AstraZeneca has signed a deal with Grünenthal worth up to $922 million in which the latter will acquire the regional rights to two of the pharma giant’s drugs.
The first acquisition of the deal will award Grünenthal the exclusive marketing rights in 33 European countries for Nexium (esomeprazole), a proton pump inhibitor which is used to treat gastroesophageal reflux conditions and ulcers. The drug continues to make significant sales despite a loss of exclusivity, having generated $248 million in total prescription sales in in-scope markets in 2017.
Reageer